Trabedersen is under clinical development by Oncotelic Therapeutics and currently in the Phase I, Phase II and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Trabedersen’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 19 Aug 2021, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Trabedersen Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Trabedersen overview

Trabedersen (OT-101) is under development for the treatment of pancreatic carcinoma, glioblastoma, myelodysplastic syndrome (MDS), malignant melanoma, high grade glioma, colorectal carcinoma and solid tumor in combination with immunotherapy (NK/IL-2) and pediatric diffuse intrinsic pontine glioma. The drug candidate is administered by intravenous, infusion and intratumoral route as a solution. It is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer). It is also under development for malignant pleural mesothelioma, pneumonia and coronavirus disease 2019 (COVID-19). It was also under development for lung cancer, renal cell cancer, prostate cancer, refractory anaplastic astrocytoma (AA) and other neoplasms.

Oncotelic Therapeutics overview

Oncotelic Therapeutics, Inc. (OTI) is a pharmaceutical and healthcare company developing investigational drugs for the treatment of orphan oncology indications. The company develops therapeutics to treat cancer and eye diseases; and anti-vascular drugs such as vascular disrupting agents. OTI is developing a product for treatment of anaplastic thyroid cancer, medullary thyroid cancer, stage IV papillary thyroid cancer, ovarian cancer, stage IV follicular thyroid cancer, and others. OTI offers development pipeline such as CA4P and Oxi4503. The company also conducts multiple clinical trials in oncology to discover small-molecule anticancer agents belong to benzosuberene class of compound. It operates through researchers in the University of Florida and the University of Arhus on anti-angiogenic and anti-metastatic agents. Oxigene is headquartered in South San Francisco, California, the US.

Quick View Trabedersen LOA Data

Report Segments
  • Innovator
Drug Name
  • Trabedersen
Administration Pathway
  • Intratumor
  • Intravenous
  • Parenteral
Therapeutic Areas
  • Infectious Disease
  • Oncology
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.